UnitedHealth
NYSE: UNH
UnitedHealth Group is a leading American healthcare company operating through two major businesses: UnitedHealthcare, which provides health insurance and medical benefit plans for individuals, employers and government programmes, and Optum, which delivers healthcare services, pharmacy benefits, data analytics and technology solutions. UnitedHealthcare is its health insurance business, while Optum is the part driving its healthcare services, pharmacy and technology operations.
- Sector
- Health Services
- Industry
- Managed Health Care
- Employees
- 390,000
- Website
- unitedhealthgroup.com ↗
The forecast figures are tipranks’s, read on 2026-11-16 and linked below.
The company facts and financials are CNN Business’s, read on 2026-11-16 and linked below.
UnitedHealth forecast
The forecast in short
tipranks records 17 analyst ratings on UnitedHealth and summarises them as “Strong Buy”. Their average 12-month price target is USD 482.69 (18.46% Upside). Its tipranks score is 7 out of 10 — Neutral. These are tipranks’s figures as read on 2026-11-16, not CariBroker’s own view, and nothing here is advice to buy or sell.
Market cap
USD 313.53 B
≈ RM 1.28 T
Share price
USD 349.91
≈ RM 1431.34 · 18 Nov close
#39World ranking
tipranks score
Neutral
Analyst ratings
Strong Buy
- Buy1482%
- Hold318%
- Sell00%
tipranks’s own summary of the 17 ratings above.
12 months price forecast
USD 482.69 18.46% Upside
As tipranks publishes it. CariBroker has not recalculated any of it.
Financials
Q3 earnings, quarter ending Sep 29, 2026
| Measure | Q3 2026 | 1-year change |
|---|---|---|
| Total revenue | 112.69B | 0.46% down |
| Net income | 4.11B | 41000.00% up |
| Earnings per share | 4.56 | 76.21% up |
| Net profit margin | 3.65% | 75.77% up |
| Free cash flow | 4.26B | 2565.00% up |
| Debt-to-equity ratio | 0.76 | 9.43% down |
Revenue and net income, last 4 quarters
Total revenueNet income
Analyst profiles: who made each call, and when
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Elizabeth Anderson CFA | Evercore ISI | Buy | USD 480 | 2026-11-10 |
| Lance Wilkes | Bernstein | Buy | USD 500 | 2026-11-04 |
| Stephen Baxter | Wells Fargo | Buy | USD 487 | 2026-10-27 |
| Erin Wright | Morgan Stanley | Buy | USD 531 | 2026-10-27 |
| Ann Hynes | Mizuho Securities | Buy | USD 500 | 2026-10-22 |
Show all 25
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Ben Hendrix | RBC Capital | Buy | USD 498 | 2026-10-19 |
| Lisa Gill | J.P. Morgan | Buy | USD 524 | 2026-10-16 |
| Whit Mayo | Leerink Partners | Buy | USD 472 | 2026-10-15 |
| Ryan Langston | TD Cowen | Hold | USD 402 | 2026-10-15 |
| Parker Snure | Raymond James | Buy | USD 450 | 2026-10-15 |
| Andrew Mok CFA | Barclays | Buy | USD 440 | 2026-10-14 |
| Kevin Fischbeck | Bank of America Securities | Buy | USD 512 | 2026-10-14 |
| Jessica Tassan | Piper Sandler | Buy | USD 504 | 2026-10-14 |
| Michael Ha | Robert W. Baird | Hold | USD 427 | 2026-10-14 |
| Scott Fidel | Goldman Sachs | Buy | USD 506 | 2026-10-13 |
| A.J. Rice | UBS | Buy | USD 490 | 2026-10-12 |
| Hans Engel | Erste Group | Hold | N/A | 2026-10-08 |
| George Hill | Deutsche Bank | Hold | N/A | 2026-08-03 |
| David S Macdonald | Truist Financial | Buy | USD 500 | 2026-07-17 |
| Michael Wiederhorn | Oppenheimer | Buy | USD 500 | 2026-07-17 |
| David Toung | Argus Research | Buy | USD 470 | 2026-07-17 |
| Matthew Gillmor CFA | KeyBanc | Buy | USD 475 | 2026-07-14 |
| Sidharth Sahoo | HSBC | Hold | USD 380 | 2026-07-06 |
| David Windley | Jefferies | Buy | USD 373 | 2026-04-20 |
| Sarah James | Cantor Fitzgerald | Buy | USD 440 | 2026-01-28 |
Investment strengths
Strong cash generation
UnitedHealth’s substantial operating and free cash flow supports investment across insurance, pharmacy, care delivery, and technology services while funding dividends and other capital needs. Free cash flow has also generally tracked earnings well, indicating meaningful underlying cash conversion despite recent growth volatility.
Diversified healthcare platform
The combination of UnitedHealthcare and Optum gives UnitedHealth multiple revenue streams across the healthcare value chain, reducing reliance on any single product or customer category. Its scale across benefits, pharmacy, care, and data services can support cross-segment capabilities and sustained relevance.
Medicare and Optum improvement
Improving Medicare margins and Optum Health’s large patient base provide identifiable avenues for earnings recovery and expansion. Progress toward the stated Optum margin range, together with value-based care and post-acute opportunities, could strengthen profitability over multiple quarters.
People also ask
What is the 12-month price target for UnitedHealth (UNH)?
tipranks publishes an average 12-month price target of USD 482.69 (18.46% Upside), as read on 2026-11-16. The highest target is USD 531 and the lowest is USD 402. A price target is an analyst’s estimate of where a share might trade, not a promise, and CariBroker gives no investment advice.
How many analysts cover UnitedHealth (UNH)?
tipranks records 17 analyst ratings: 14 buy, 3 hold and 0 sell, which it summarises as “Strong Buy”, as read on 2026-11-16.
What is the tipranks score for UnitedHealth (UNH)?
tipranks scores it 7 out of 10 and calls that “Neutral”, as read on 2026-11-16. The score is tipranks’s, not CariBroker’s, and CariBroker does not rate listed shares.
Is this CariBroker’s own forecast for UnitedHealth?
No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. CariBroker checks financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.
Disclaimer
CariBroker provides information only and does not provide investment, financial or legal advice.
Check another company
Search every bank, broker and alert list in one place
